These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 33866649)

  • 1. Validation of factor VIII activity for monitoring standard and extended half-life products and correlation to thrombin generation assays.
    Augustsson C; Norström E; Lind V; Martin M; Astermark J; Strandberg K
    Haemophilia; 2021 May; 27(3):494-500. PubMed ID: 33866649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring standard and extended half-life products in hemophilia: Assay discrepancies for factor VIII and IX in pre- and postinfusion samples.
    Augustsson C; Norström E; Andersson NG; Zetterberg E; Astermark J; Strandberg K
    Res Pract Thromb Haemost; 2020 Oct; 4(7):1114-1120. PubMed ID: 33134777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimation of Nuwiq
    Tiefenbacher S; Albisetti M; Baker P; Kappert G; Kitchen S; Kremer Hovinga JA; Pouplard C; Scholz U; Ternisien C; Borgvall C; Vicente T; Belyanskaya L; Walter O; Oldenburg J;
    Haemophilia; 2019 Jul; 25(4):708-717. PubMed ID: 31106957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor VIII and IX assays for post-infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT).
    Jeanpierre E; Pouplard C; Lasne D; Le Cam Duchez V; Eschwege V; Flaujac C; Galinat H; Harzallah I; Proulle V; Smahi M; Sobas F; Stepina N; Toulon P; Voisin S; Ternisien C; Nougier C;
    Eur J Haematol; 2020 Aug; 105(2):103-115. PubMed ID: 32277501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accurate measurement of extended half-life and unmodified factor VIII low levels with one-stage FVIII assays is dependent on the matrix of calibration curves.
    Van den Bossche D; Toelen J; Schoeters J; Van Horenbeeck I; Vanlinthout I; Debasse M; Peerlinck K; Jacquemin M
    Haemophilia; 2019 Jan; 25(1):e19-e26. PubMed ID: 30589148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring of different factor VIII replacement products using a factor VIII one-stage clotting assay on cobas t 511/711 analysers.
    Ketteler C; Hoffmann I; Davidson S; Tiede A; Richter N
    Haemophilia; 2021 Nov; 27(6):e704-e712. PubMed ID: 34590394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Factor VIII assays in treated hemophilia A patients].
    Lasne D; Pouplard C; Nougier C; Eschwege V; Le Cam Duchez V; Proulle V; Smahi M; Harzallah I; Voisin S; Toulon P; Sobas F; Galinat H; Flaujac C; Ternisien C; Jeanpierre E;
    Ann Biol Clin (Paris); 2019 Feb; 77(1):53-65. PubMed ID: 30799298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors.
    Bowyer A; Kitchen S; Maclean R
    Haemophilia; 2020 May; 26(3):536-542. PubMed ID: 32249990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analytical variation in factor VIII one-stage and chromogenic assays: Experiences from the ECAT external quality assessment programme.
    van Moort I; Meijer P; Priem-Visser D; van Gammeren AJ; Péquériaux NCV; Leebeek FWG; Cnossen MH; de Maat MPM
    Haemophilia; 2019 Jan; 25(1):162-169. PubMed ID: 30488994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the thrombin generation profiles of four different rFVIII products in FVIII-deficient plasma using FIXa and FXIa activation.
    Brophy DF; Martin EJ; Ninivaggi M; Mohammed BM; Barrett JC; Kuhn J; Nolte ME; Waters EK; Ezban M
    Haemophilia; 2018 Sep; 24(5):815-822. PubMed ID: 30112856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended Half-Life Factor VIII/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management.
    Müller J; Goldmann G; Marquardt N; Pötzsch B; Oldenburg J
    Hamostaseologie; 2020 Nov; 40(S 01):S15-S20. PubMed ID: 33187006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A critical appraisal of one-stage and chromogenic assays of factor VIII activity.
    Peyvandi F; Oldenburg J; Friedman KD
    J Thromb Haemost; 2016 Feb; 14(2):248-61. PubMed ID: 26663865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance evaluation of Revohem
    Suzuki A; Suzuki N; Kanematsu T; Shinohara S; Arai N; Kikuchi R; Matsushita T
    Int J Lab Hematol; 2019 Oct; 41(5):664-670. PubMed ID: 31271527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Area under the curve: Comparing the value of factor VIII replacement therapies in haemophilia A.
    Persson S; Berndt C; Engstrand S; Trinczek A; Carlsson KS; Berntorp E
    Haemophilia; 2023 Jan; 29(1):145-155. PubMed ID: 36445343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of a next generation factor VIII mimetic bispecific antibody (Mim8) on assays of factor VIII activity and thrombin generation.
    Bowyer AE; Kitchen S; Ezban M
    J Thromb Haemost; 2023 Mar; 21(3):480-487. PubMed ID: 36696203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring rFVIII prophylaxis dosing using global haemostasis assays.
    Al Hawaj MA; Martin EJ; Venitz J; Barrett JC; Kuhn JG; Nolte ME; Brophy DF
    Haemophilia; 2013 May; 19(3):409-14. PubMed ID: 23510278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factor VIII assay variability in postinfusion samples containing full length and B-domain deleted FVIII.
    Kitchen S; Jennings I; Makris M; Kitchen DP; Woods TA; Walker ID
    Haemophilia; 2016 Sep; 22(5):806-12. PubMed ID: 27217329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International comparative field study evaluating the assay performance of AFSTYLA in plasma samples at clinical hemostasis laboratories.
    St Ledger K; Feussner A; Kalina U; Horn C; Metzner HJ; Bensen-Kennedy D; Blackman N; Veldman A; Stowers A; Friedman KD
    J Thromb Haemost; 2018 Mar; 16(3):555-564. PubMed ID: 29274194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicentre pharmacokinetic evaluation of rFVIII-Fc (efmoroctocog alfa) in a real life and comparison with non-extended half-life FVIII concentrates.
    Pouplard C; Sattler L; Ryman A; Eschwege V; De Maistre E; Flaujac C; Szymezak J; Grand F; Repesse Y; Galinat H; Donnard M; Ternisien C; Iorio A; Chelle P; Jeanpierre E;
    Haemophilia; 2020 Mar; 26(2):282-289. PubMed ID: 32107819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories.
    Sommer JM; Moore N; McGuffie-Valentine B; Bardan S; Buyue Y; Kamphaus GD; Konkle BA; Pierce GF
    Haemophilia; 2014 Mar; 20(2):294-300. PubMed ID: 24261554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.